Caprion Biosciences - Company & Market Research Reports

Caprion Pharmaceuticals is a drug discovery and development company engaged in the discovery and development of proteomics pharmaceutical products in oncology and infectious disease. The company's clinical-stage programs include Shigamabs, a product for the treatment of shigatoxin-producing bacterial infections, and CAP-232, a therapy with potential efficacy in multiple oncology indications. Caprion Pharmaceuticals, Inc. was founded in 1998 and is based in Montreal, Canada.